Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316605 | 1.00 | OR51E2 (0.39) | OR51E2ALDH1A1MAPTPTGS1PDE4A | |
| SCHEMBL28390971 | 0.81 | OR51E2 (0.38) | OR51E2ALDH1A1MAPTPTGS1PDE4A | |
| SCHEMBL28651642 | 0.80 | SLC1A3 (0.36) | ALDH1A1MAPTPTGS1HMGCRCHRM1 | |
| SCHEMBL611896 | 0.79 | CHRM1 (0.33) | OR51E2ALDH1A1MAPTPTGS1CHRM1 | |
| SCHEMBL12891264 | 0.78 | CA2 (0.41) | ALDH1A1MAPTPTGS1HMGCRCHRM1 | |
| SCHEMBL2631146 | 0.78 | CA2 (0.41) | ALDH1A1MAPTPTGS1HMGCRCHRM1 | |
| SCHEMBL12374968 | 0.78 | PRKCA (0.30) | — | |
| SCHEMBL276534 | 0.78 | CA2 (0.41) | ALDH1A1MAPTPTGS1HMGCRCHRM1 | |
| SCHEMBL1941442 | 0.76 | TDP1 (0.43) | MAPTHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL636537 | 0.76 | GABRR1 (0.37) | OR51E2ALDH1A1MAPTPTGS1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4592332-A1 | METHOD FOR PREPARING ALKYL POLY(3-HYDROXYPROPIONATE), ALKYL POLY(3-HYDROXYPROPIONATE), AND COMPOSITION COMPRISING SAME | LG CHEM, LTD. (KR) | 2025-07-30 | — | — | EP | disclosed |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023092817-A1 | ADDITIVE FOR 193 NM DRY PHOTORESIST AND PREPARATION METHOD FOR AND APPLICATION OF ADDITIVE | 上海新阳半导体材料股份有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-11242308-B2 | Methods for producing an ester of an alpha, beta-unsaturated carboxylic acid | CARGILL, INCORPORATED (US) | 2022-02-08 | — | — | US | disclosed |
| EP-2922535-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| CN-112480121-A | Polycyclic derivative and preparation thereof | 四川海思科制药有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200369591-A1 | METHODS FOR PRODUCING AN ESTER OF AN ALPHA, BETA-UNSATURATED CARBOXYLIC ACID | CARGILL, INCORPORATED (US) | 2020-11-26 | — | — | US | disclosed |
| EP-2403920-A2 | A METHOD FOR THE MANUFACTURE OF NANOPARTICLE COMPLEXES AND TRIBLOCK POLYMER LIGANDS AND PRODUCTS THEREOF | Centrum für Angewandte Nanotechnologie (CAN) GmbH (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-20110105654-A1 | Method for Producing a Compound with at Least One at Least Monosubstituted Amino Group | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2011-05-05 | — | — | US | disclosed |
| US-7910587-B2 | Quinoxalinyl dipeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910587-B2 | Quinoxalinyl dipeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2276749-A1 | METHOD FOR PRODUCING A COMPOUND WITH AT LEAST ONE AT LEAST MONOSUBSTITUTED AMINO GROUP | Borealis Agrolinz Melamine GmbH (AT) | 2011-01-26 | — | — | EP | disclosed |
| WO-2010100118-A2 | A METHOD FOR THE MANUFACTURE OF NANOPARTICLE COMPLEXES AND TRIBLOCK POLYMER LIGANDS AND PRODUCTS THEREOF | CENTRUM FÜR ANGEWANDTE NANOTECHNOLOGIE (CAN) GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
| WO-2009121607-A1 | METHOD FOR PRODUCING A COMPOUND WITH AT LEAST ONE AT LEAST MONOSUBSTITUTED AMINO GROUP | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2009-10-08 | — | — | WO | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-4725620-A | 2H-pyran-2,6-(3H)-dione derivatives with anti-allergic activity | ALLERGAN, INC. (US) | 1988-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105654-A1 | Method for Producing a Compound with at Least One at Least Monosubstituted Amino Group | GNMT, PAM, SMOX | OR51E2 3546/4885ALDH1A1 583/4885MAPT 4348/4885 |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | OR51E2 4058/4885ALDH1A1 301/4885MAPT 2382/4885 |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | DPP4, CTSC, PEPD | OR51E2 4570/4885ALDH1A1 990/4885MAPT 4445/4885 |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | OR51E2 4643/4885ALDH1A1 4054/4885MAPT 3109/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | OR51E2 4653/4885ALDH1A1 4055/4885MAPT 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.